Kornimate/medical-research-clean huggingface dataset:
adapting ba for minimally verbal autistic adults

Conditions: Autism; Depression; Autism Spectrum Disorder With Impaired Functional Language; Autism Spectrum Disorder

Summary: the present study aims to adapt and evaluate the feasibility of the beatit-2 behavioral activation intervention for people with intellectual disabilities and low mood to be implemented with minimally verbal autistic individuals.

aim 1. the first phase of the project will focus on adapting the beatit-2 manual to consider specific needs of mv autistic adults. this procedure includes an intervention development group (idg), for which mv autistic adults and their supporters (i.e., someone identified as a source of support they can work with) will be recruited. aim 2. during the following phase of the project, a feasibility trial will be conducted. using the treatment manual and study procedures adapted and refined in phase 1, the trial will examine the feasibility and acceptability of beatit-mv.

Eligibility criteria:
inclusion criteria: * minimally verbal * aged 18 years or older * diagnosis of autism spectrum disorder and clinically significant depression based on clinical best estimate diagnosis using dsm-5 or diagnostic manual - intellectual disability criteria * have a support person willing to participate * live in new jersey or new york, or be within travel distance to rutgers university exclusion criteria: * not able to engage in treatment in english * current engagement in other treatment for depression * conditions that may preclude engagement in treatment sessions (e.g., active psychosis, unmanaged seizures) * high suicide risk (i.e., with a clear plan, expressed intent or recent documented attempts)

Keywords: behavioral activation
ai4hope dementia pain assessment pilot study 1

Conditions: Dementia

Summary: the pilot study will develop and test a standardized assessment toolkit that will provide conclusive information with a tolerable burden for cognitively impaired patients with dementia.

the clinical study is part of an eu-funded project on the use of artificial intelligence for patients with dementia. this study will test a digital toolkit fo assessment and monitoring of patients with mild or moderate dementia and pilot-test this toolkit for feasibility and acceptability. patients with mild to moderate dementia will be recruited for the pilot study in the six participating countries. the study population includes all types of dementia without stratification, as the aim of the study is to construct a digital assessment and intervention toolkit for clinical practice in any patient with cognitive impairment from any type of dementia. even though the final assessment and intervention toolkit could also be useful for patients with advanced dementia and more severe cognitive impairment, the pilot study will recruit only patients with mild or moderate dementia, who will still be able to provide informed consent, and who will be able to self-assess at least minimum patient-related outcome or patient-related experience measures to validate the behavioural and observational scales and biomarkers used in the toolkit. patients with dementia treated in the participating study centers will be screened for inclusion criteria and, if suitable will be invited to participate. the study will be performed for seven days, with optional extension to 30 days according to patients' preferences. patients with baseline data and at least one intervention performed from the digital toolkit and data completed before and after that intervention will be included in the evaluation.

Eligibility criteria:
inclusion criteria: * mild or moderate dementia of any type * able to provide informed consent, or consent from surrogate decision maker * able to self-assess patient-related outcome (prom) or experience (prem) measures exclusion criteria: * ongoing delir * severe cognitive impairment (mmse \< 10 \[22\]) * unable to provide informed consent * life expectancy estimated less than 3 months
higher levothyroxine requirements after right-side hemithyroidectomy

Conditions: Hemithyroidectomy; Hypothyroidism

Summary: 459 adult patients who received a hemithyroidectomy at the department of general surgery, division of endocrine surgery and a follow-up visit (3-12 months post-surgery) at the thyroid outpatient clinic of the department of endocrinology and metabolism, medical university of vienna between 1994 and 2018 were identified and investigated in this retrospective study. the aim of this study was to investigate whether patients post right side hemithyroidectomy require a higher mean levothyroxine dosage than patients after left lobe hemithyroidectomy as the right thyroid lobe is bigger than the left lobe. further, we aimed at developing a better post-surgery thyroid dosage prediction model.

in most patients, the right lobe of the thyroid gland is larger than the left lobe. after a hemithyroidectomy, the remaining lobe grows by up to 30% to compensate for the loss. however, thyroxine replacement is still necessary for 22% to 60% of all patients. the aim of this study is to investigate whether a right-lobe hemithyroidectomy predisposes to a higher postoperative dose of levothyroxine. patients and methods in a retrospective cohort study, 459 patients over the age of 18 years who underwent a hemithyroidectomy at the department of general surgery, division of endocrine surgery and a follow-up (3-12 months post-surgery) visit at the thyroid outpatient clinic of the department of endocrinology and metabolism between 1994 and 2018 were investigated. the study was approved by the local ethics committee and performed in accordance with the declaration of helsinki. the work has been reported in line with the strocss criteria. the patients were identified via data extraction from a university hospital-wide research, documentation and analysis (rda) database. in a second step, further information necessary for the analysis (ultrasound data on pre-surgery thyroid volume, pre-surgery tsh, side and date of hemithyroidectomy, surgery protocol, underlying thyroid disease, type and dosage of treatment, age, weight, height, thyrotropin (tsh), free t4 (ft4), free t3 (ft3)) were extracted from the internal electronic health record system. patients who had either received radiation therapy had undergone previous thyroid surgery, surgery on the contralateral lobe, had pre-existing hypothyroidism, an autoimmune disease of the thyroid or were pregnant were excluded from the analysis. 33 patients were excluded due to additional surgery on the contralateral lobe resulting in a total of 426 patients. pre-surgery ultrasound thyroid volume was calculated with the volumetric ellipsoid method (height × width × depth × correction factor 0.524).

Eligibility criteria:
inclusion criteria: * 18 years * males and females * st.p. hemithyroidectomy exclusion criteria: * radiation therapy * pregnancy * previous thyroid surgery (e.g. nodule removal surgery)

Keywords: hemithyroidectomy levothyroxine postoperative levothyroxine requirements lobectomy thyroid
dystonia coalition projects

Conditions: Dystonia

Summary: dystonia is a disorder characterized by excessive involuntary contraction of muscles with repetitive and patterned movements. the primary focal dystonias are the most common type of dystonia and include limb dystonias (like writer's cramp), cervical dystonia (spasmodic torticollis), laryngeal dystonias (like spasmodic dysphonia), and craniofacial dystonias (like blepharospasm). the purpose of this study is to create resources to help learn more about the primary focal dystonias and to develop and validate various dystonia rating scales.

this collaborative, international effort has two primary goals. the first is to create a biospecimen repository and associated clinical database to be used as a resource for dystonia and related disease research. the second goal is to create and validate various rating scales for focal dystonias to be used during a typical clinical examination. across sites, the investigators hope to enroll at least 5,000 adult patients. subjects of this study will be asked to complete a neurological exam which will be videotaped, complete some questionnaires, and donate a blood sample. a study visit will take between 45 minutes and 1 hour depending upon which portions of the study a subject completes. a subset of subjects will be asked to return no more often than once a year for a one hour follow-up visit.

Eligibility criteria:
inclusion criteria: * diagnosed with primary dystonia * to be included in laryngeal dystonia group, nasolaryngoscopy (voice box exam) must have been completed to confirm diagnosis exclusion criteria: -any person with secondary dystonia

Keywords: cervical dystonia cranial dystonia limb dystonia
a feasibility study of wearable device in assessing respiratory condition change of patients with exacerbation of copd

Conditions: COPD Exacerbation

Summary: the study will include daily senseguard measurement of patients hospitalized with exacerbations of copd. from admission to discharge. in parallel clinical evaluation of patient's respiratory condition was done daily by routine tests and questionnaires.

a study for evaluating the feasibility of senseguard in assessing the respiratory condition change of hospitalized patients with exacerbation of copd, by monitoring respiratory parameters. the study duration for each patient will start at the time of enrollment until the patient is released, or until the optional post-discharge follow-up visit. the study will include at least one visit per day: the visit and measurement with senseguard will start prior to the first medical exacerbation treatment effect-onset given on each study day (by inhalation or iv). the measurement with senseguard will be done before and after treatment. at the investigator discretion, additional two similar visits could be performed on the same study day, with or without the admission of the medical exacerbation treatment. during the study, both the investigator and the patients will be asked to fill questionnaires to assess the patient's condition additionally, measurements that are performed and collected as a standard practice or at the request of the medical personnel as part of patient's treatment course shall be documented and used as a reference for the study device assessment.

Eligibility criteria:
inclusion criteria: 1. primary or secondary diagnosis of aecopd (acute exacerbation of chronic obstructive pulmonary disease) in patients with gold 1-4/a-d 2. who performance status ≤ 3 3. provision of signed and dated informed consent form. 4. male or female, aged ≥18. 5. ability and stated willingness to adhere to the study regimen and availability for the duration of the study. exclusion criteria: 3. inability to provide informed consent including patients still impacted by the use of narcotics as part of emergency care. 4. intubated patients or patients undergoing a bipap/cpap/nhf treatment and are medically not able to suspend the treatment for the required duration of the visits or expected intolerance of the sensor in their face due to severe respiratory distress. 5. presence of implanted electronic device intended to regulate cardiac activity (e.g., pacemaker or cardioverter/defibrillator). 6. pregnancy or lactation. 7. known allergic reactions to materials used in the components of the senseguard™ system, i.e. polyethylene or silicon, or gold, nickel, copper or alloys containing any of the above. 8. participation in another study that is related to treatment of the respiratory condition.
a comparison of the safety and efficacy of two different regimens of levofloxacin in the treatment of acute bacterial sinusitis(sinus infection) in adults.

Conditions: Sinusitis

Summary: the purpose of this study is to evaluate the effectiveness and safety of two antibiotic regimens in the treatment of acute bacterial sinusitis (sinus infection) in non-hospitalized adult patients. a 5-day course of 750 milligrams of levofloxacin given by mouth once daily will be compared to a 10-day course of 500 milligrams of levofloxacin given by mouth once daily.

when treating sinus infections (sinusitis) caused by bacteria, the traditional duration of therapy is between 10 and 14 days. in this randomized, double-blind study, 5 days of 750 milligrams of levofloxacin given once daily will be compared to 10 days of 500 milligrams of levofloxacin in the treatment of non-hospitalized adult patients who have acute bacterial sinusitis. to prevent the study doctor, study staff and patients from knowing which study drug they are taking, all study drug will manufactured to look the same and patients on the 5-day regimen will be given placebo for the last 5 days of their participation in the study. patients will have a sinus specimen collected at the first visit. safety evaluations will be conducted. the objective of the study is to demonstrate that, in the treatment of acute bacterial sinus infections, a 5-day course of 750 milligrams of levofloxacin given once daily is at least as effective as a 10-day course of 500 milligrams of levofloxacin given once daily and is well tolerated. patients will take by mouth 750 milligrams levofloxacin capsules once daily for 5 days followed by placebo capsules once daily for 5 days, or 500 milligrams levofloxacin capsules once daily for 10 days.

Eligibility criteria:
inclusion criteria: * diagnosis of acute bacterial sinusitis, defined by clinical signs and symptoms lasting for less than 28 days and the presence of visible nasal infection, and confirmed by computed tomography (ct) or standard sinus x-rays * two or fewer episodes of bacterial sinusitis within the preceding 12 months * willing to undergo maxillary sinus puncture or endoscopy exclusion criteria: * chronic sinusitis * use of systemic antibiotics within the past 72 hours * presence or history of serious complications of sinusitis * surgery for treating sinusitis * required daily use of more than 20 milligrams of prednisone (oral steroid) * cystic fibrosis

Keywords: sinus infection acute bacterial sinusitis sinusitis bacterial sinus infection
detection of homologous recombination pathway gene mutations in circulating tumour dna from brca-mutated ovarian cancer patients receiving first-line parp inhibitor maintenance therapy

Conditions: Ovarian Cancer

Summary: this is an interventional (category 2), prospective, multicentric cohort study designed to demonstrate that the search, based on circulating tumour dna analysis, for a brca1/2 reversion mutation leading to restoration of its protein function enables early identification of disease progression in brca1/2 mutant patients treated as first-line maintenance with a parp inhibitor (olaparib alone or in combination with bevacizumab) for ovarian cancer. for this study, a total of 9 blood samples will be taken from patients who will undergo a full 24-month treatment regimen. apart from the study procedure (blood sampling), all examinations carried out in this study, treatment with olaparib (alone or combined with bevacizumab) and patient follow-up procedures will be carried out as part of routine care in accordance with the standard practices of each investigating site. 130 patients will take part in the study, and each patient will be followed for 24 months.


Eligibility criteria:
inclusion criteria: 1. patient with an epithelial ovarian cancer. 2. patient with a brca 1 or 2 somatic and/or constitutional mutation previously confirmed and validated by an approved laboratory. 3. patient due to start first-line maintenance treatment with olaparib alone (parp inhibitor) or in combination with bevacizumab. 4. age ≥ 18 years at the time of signing the consent. 5. who ≤ 1. 6. patient affiliated to a social security scheme in france. 7. patient having signed informed consent prior to inclusion in the study and prior to any specific procedure for the study. exclusion criteria: 1. other cancer under treatment. 2. olaparib treatment already initiated. 3. indication for treatment with a parp inhibitor other than olaparib. 4. any pathology contraindicating the sample collection procedures required by the study. 5. any psychological, family, geographical or sociological condition that makes it impossible to comply with medical monitoring and/or the procedures laid down in the study protocol. 6. subjects deprived of their liberty or under legal protection.
radial reload laparoscopic lar case series

Conditions: Colorectal Cancer

Summary: to evaluate the radial reload stapler during laparoscopic low anterior resection (lar) or anterior proctosigmoidectomy for rectal cancer by assessing the primary and secondary endpoints.


Eligibility criteria:
inclusion criteria: 1. the subject is able to understand and sign informed consent form. 2. the subject is between 18-85 years of age. 3. the subject is anticipated to undergo a resection of the rectum with anastomosis below the peritoneal reflection. 4. the subject is anticipated to undergo mobilization and stapling of the rectum laparoscopically. exclusion criteria: 1. any female patient, who is pregnant, suspected pregnant, or nursing. 2. the participant is unable or unwilling to comply with the study requirements, follow-up schedule. 3. the participant has co-morbidities which, in the opinion of the investigator, will not be appropriate for the study.
mechanisms of inflammation, immunity, islet cell and intestinal hormone changes in youth at risk for diabetes

Conditions: Obesity; PreDiabetes; Adolescent Obesity; Inflammation; Metabolic Problems; Insulin Resistance; Gut Microbiome; Immunity; Beta Cell Dysfunction; Gut Hormones

Summary: this study intends to assess the role of inflammation in insulin resistant conditions (i.e., obesity and pre-diabetes) and the subsequent development of disease, such as type 2 diabetes (t2d) and cardiovascular disease (cvd), in the adolescent population.

this study proposes to characterize inflammatory biomarkers, insulin resistance and fecal microbiome composition in obese/pre-diabetic adolescents after glucose ingestion, followed by an oral fat tolerance test on a separate visit. lipoprotein abnormalities and intestinal biomarkers, post-lipid ingestion, will also be evaluated. the primary aim is to assess the role of inflammation in insulin resistant conditions (i.e., obesity and pre-diabetes) and the subsequent development of disease, such as type 2 diabetes (t2d) and cardiovascular disease (cvd), in the adolescent population.

Eligibility criteria:
inclusion criteria: 1. adolescents aged 12 - 18 years old with obesity (defined as body mass index (bmi) \>97th percentile based on their age- and sex-specific world health organization growth chart) exclusion criteria: 1. known type 2 diabetes 2. diabetes secondary to medication or surgery 3. antibodies suggestive of type 1 diabetes 4. pregnancy 5. were born by c-section 6. developmental delay precluding assent/consent 7. acute illness within the past 3 days (chills, fever, vomiting \> 1x, or diarrhea \> 3x) 8. taking medications that influence glucose (e.g., steroids, metformin) or lipids (e.g., statins) 9. have taken prescribed medicine/antibiotics in the three months prior to clinic or study visit 10. significant chronic illness (e.g., cushing's disease, craniopharyngioma, hypothalamic obesity, etc.) 11. lactose intolerance and/or milk allergy (study visit day 2 only) 12. bariatric surgery
radiological spectrum of fatty liver correlate with high resolution ultrasonography of fibrosis and cirrhosis

Conditions: Fibrosis; Cirrhosis

Summary: fatty liver is a condition in which fat builds up in liver. it is very common health issue.it is major public health problems in the world. there is particular concern because fatty liver causes mortality among patients. the incidence and prevalence of disease vary with time. fibrosis is thickening of connective tissues which is usually as a result of injury and long term inflammation. cirrhosis is severe scarring of liver which is caused by long term liver damage. the scar tissue replaces healthy tissues which leads to loss of liver function. the objective of study is to look into radiographic features of fatty liver disease. the high resolution ultrasonography will give more detailed view of disease. the study inclued 150 participants.

the other liver conditions like fibrosis and cirrhosis are also examined and correlated with fatty liver disease. the ct and mri are used to compare with hr ultrasonographic findings. descriptive statistics and comparative statistics are used to interpret data.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of fatty liver (steatosis), fibrosis, or cirrhosis. * patient consent to undergo imaging and participate in the study. exclusion criteria: * other liver diseases: exclusion of patients with other significant liver conditions (e.g., viral hepatitis, autoimmune liver diseases) unless specified. * pregnant women may be excluded due to imaging concerns. * poor quality or incomplete imaging studies. * presence of other severe systemic illnesses that could affect liver function or imaging. * recent liver surgeries or invasive procedures that might affect imaging results